This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BMS-954561, EHT/AGN001, AGN-209323
Description: EHT/AGN001 is an oral drug discovered using ExonHit's DATAS technology, which looks for alternatively spliced messenger RNA to identify disease targets. The specific target of the drug has not been identified.
Allergan and Exonhit
In 2003, Allergan and ExonHit initiated a drug discovery collaboration to identify, develop and commercialise drugs targeted at the treatment of neurodegenerative diseases, pain and ophthalmology. Under the terms of the agreement, Allergan will assume responsibility for the ongoing clinical development and commercialisation of EHT/AGN001. Contingent upon progress, ExonHit will receive milestone payments and royalties upon commercialisation.
In January 2009, this collaboration was extended through December 2011.
In November 2011, this collaboration was extended through December 2013.
Bristol-Myers Squibb and Allergan
In March 2010, Bristol-Myers Squibb and Allergan announced a global agreement for the development and commercialization of EHT/AGN 0001 (AGN-209323). Under the terms of the agreement, Allergan will grant to Bristol-Myers Squibb exclusive worldwide rights to develop, manufacture and commercialize AGN-209323 and backup...See full deal structure in Biomedtracker
Partners: Diaxonhit Group
EHT/AGN 0001 News
Additional information available to subscribers only: